Cargando…

Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease, with high mortality. Currently, the aetiology and the pathology of IPF are poorly understood, with both innate and adaptive responses previously being implicated in the disease pathogenesis. Heat shoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Ross, Mathur, Abhinav, Nicol, Lisa M., Walker, Jeremy J., Przybylski, Alexander A., Mackinnon, Alison C., Howie, Sarah E. M., Wallace, William A. H., Dransfield, Ian, Hirani, Nik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487088/
https://www.ncbi.nlm.nih.gov/pubmed/31098385
http://dx.doi.org/10.1155/2019/1845128
_version_ 1783414438306512896
author Mills, Ross
Mathur, Abhinav
Nicol, Lisa M.
Walker, Jeremy J.
Przybylski, Alexander A.
Mackinnon, Alison C.
Howie, Sarah E. M.
Wallace, William A. H.
Dransfield, Ian
Hirani, Nik
author_facet Mills, Ross
Mathur, Abhinav
Nicol, Lisa M.
Walker, Jeremy J.
Przybylski, Alexander A.
Mackinnon, Alison C.
Howie, Sarah E. M.
Wallace, William A. H.
Dransfield, Ian
Hirani, Nik
author_sort Mills, Ross
collection PubMed
description RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease, with high mortality. Currently, the aetiology and the pathology of IPF are poorly understood, with both innate and adaptive responses previously being implicated in the disease pathogenesis. Heat shock proteins (Hsp) and antibodies to Hsp in patients with IPF have been suggested as therapeutic targets and prognostic biomarkers, respectively. We aimed to study the relationship between the expression of Hsp72 and anti-Hsp72 antibodies in the BAL fluid and serum Aw disease progression in patients with IPF. METHODS: A novel indirect ELISA to measure anti-Hsp72 IgG was developed and together with commercially available ELISAs used to detect Hsp72 IgG, Hsp72 IgGAM, and Hsp72 antigen, in the serum and BALf of a cohort of IPF (n = 107) and other interstitial lung disease (ILD) patients (n = 66). Immunohistochemistry was used to detect Hsp72 in lung tissue. The cytokine expression from monocyte-derived macrophages was measured by ELISA. RESULTS: Anti-Hsp72 IgG was detectable in the serum and BALf of IPF (n = 107) and other ILDs (n = 66). Total immunoglobulin concentrations in the BALf showed an excessive adaptive response in IPF compared to other ILDs and healthy controls (p = 0.026). Immunohistochemistry detection of C4d and Hsp72 showed that these antibodies may be targeting high expressing Hsp72 type II alveolar epithelial cells. However, detection of anti-Hsp72 antibodies in the BALf revealed that increasing concentrations were associated with improved patient survival (adjusted HR 0.62, 95% CI 0.45-0.85; p = 0.003). In vitro experiments demonstrate that anti-Hsp72 complexes stimulate macrophages to secrete CXCL8 and CCL18. CONCLUSION: Our results indicate that intrapulmonary anti-Hsp72 antibodies are associated with improved outcomes in IPF. These may represent natural autoantibodies, and anti-Hsp72 IgM and IgA may provide a beneficial role in disease pathogenesis, though the mechanism of action for this has yet to be determined.
format Online
Article
Text
id pubmed-6487088
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64870882019-05-16 Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF Mills, Ross Mathur, Abhinav Nicol, Lisa M. Walker, Jeremy J. Przybylski, Alexander A. Mackinnon, Alison C. Howie, Sarah E. M. Wallace, William A. H. Dransfield, Ian Hirani, Nik J Immunol Res Research Article RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease, with high mortality. Currently, the aetiology and the pathology of IPF are poorly understood, with both innate and adaptive responses previously being implicated in the disease pathogenesis. Heat shock proteins (Hsp) and antibodies to Hsp in patients with IPF have been suggested as therapeutic targets and prognostic biomarkers, respectively. We aimed to study the relationship between the expression of Hsp72 and anti-Hsp72 antibodies in the BAL fluid and serum Aw disease progression in patients with IPF. METHODS: A novel indirect ELISA to measure anti-Hsp72 IgG was developed and together with commercially available ELISAs used to detect Hsp72 IgG, Hsp72 IgGAM, and Hsp72 antigen, in the serum and BALf of a cohort of IPF (n = 107) and other interstitial lung disease (ILD) patients (n = 66). Immunohistochemistry was used to detect Hsp72 in lung tissue. The cytokine expression from monocyte-derived macrophages was measured by ELISA. RESULTS: Anti-Hsp72 IgG was detectable in the serum and BALf of IPF (n = 107) and other ILDs (n = 66). Total immunoglobulin concentrations in the BALf showed an excessive adaptive response in IPF compared to other ILDs and healthy controls (p = 0.026). Immunohistochemistry detection of C4d and Hsp72 showed that these antibodies may be targeting high expressing Hsp72 type II alveolar epithelial cells. However, detection of anti-Hsp72 antibodies in the BALf revealed that increasing concentrations were associated with improved patient survival (adjusted HR 0.62, 95% CI 0.45-0.85; p = 0.003). In vitro experiments demonstrate that anti-Hsp72 complexes stimulate macrophages to secrete CXCL8 and CCL18. CONCLUSION: Our results indicate that intrapulmonary anti-Hsp72 antibodies are associated with improved outcomes in IPF. These may represent natural autoantibodies, and anti-Hsp72 IgM and IgA may provide a beneficial role in disease pathogenesis, though the mechanism of action for this has yet to be determined. Hindawi 2019-04-11 /pmc/articles/PMC6487088/ /pubmed/31098385 http://dx.doi.org/10.1155/2019/1845128 Text en Copyright © 2019 Ross Mills et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mills, Ross
Mathur, Abhinav
Nicol, Lisa M.
Walker, Jeremy J.
Przybylski, Alexander A.
Mackinnon, Alison C.
Howie, Sarah E. M.
Wallace, William A. H.
Dransfield, Ian
Hirani, Nik
Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
title Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
title_full Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
title_fullStr Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
title_full_unstemmed Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
title_short Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
title_sort intrapulmonary autoantibodies to hsp72 are associated with improved outcomes in ipf
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487088/
https://www.ncbi.nlm.nih.gov/pubmed/31098385
http://dx.doi.org/10.1155/2019/1845128
work_keys_str_mv AT millsross intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT mathurabhinav intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT nicollisam intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT walkerjeremyj intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT przybylskialexandera intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT mackinnonalisonc intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT howiesarahem intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT wallacewilliamah intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT dransfieldian intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf
AT hiraninik intrapulmonaryautoantibodiestohsp72areassociatedwithimprovedoutcomesinipf